SLC5A2 and type 2 diabetes mellitus: In the dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10) trial, two different doses of dulaglutide (0.75 or 1.5 mg) or placebo were assigned to patients previously receiving SGLT2 inhibitors with or without metformin [38].